RANDOMIZED, OPEN LABEL, PHASE 3 CLINICAL STUDY TO EVALUATE THE EFFECT OF THE ADDITION OF CP-751,871 TO GEMCITABINE AND CISPLATIN IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER •To determine whether addition of CP-751,871 prolongs the survival of NSCLC patients treated with gemcitabine and cisplatin.

• Country None
• organs None
• Specialty None

A PHASE 2, RANDOMIZED, NON-COMPARATIVE, TWO-ARM OPEN LABEL, MULTIPLE-CENTER STUDY OF CP-751,871 IN COMBINATION WITH DOCETAXEL/PREDNISONE IN CHEMOTHERAPY- NAÏVE (ARM A) AND DOCETAXEL/PREDNISONE REFRACTORY (ARM B) PATIENTS WITH HORMONE INSENSITIVE PROSTATE CANCER Primary Objective: • To assess the efficacy, in term of PSA response rate, of multiple doses of CP 751,871 in combination with docetaxel and prednisone in patients with HRPC.

• Country None
• organs None
• Specialty None

Tofacitinib MRI in Early Rheumatoid Arthritis To estimate the effect of CP-690,550 administered as a DMARD monotherapy or in combination with MTX vs MTX alone on changes from baseline in wrist and metacarpophalangeal joints (MCP) bone marrow edem...

• Country None
• organs None
• Specialty None

A RANDOMISED, PHASE 3 STUDY OF DOCETAXEL IN COMBINATION WITH SUNITINIB VERSUS DOCETAXEL IN THE FIRST-LINE TREATMENT OF ADVANCED BREAST CANCER PATIENTS To demonstrate that the combination of docetaxel with sunitinib is superior to docetaxel in prolonging PFS in patients with advanced breast cancer.

• Country None
• organs None
• Specialty None

LONG TERM SAFETY AND EFFICACY STUDY OF PREGABALIN IN SUBJECTS WITH GENERALIZED ANXIETY DISORDER To characterize the safety and efficacy of pregabalin in subjects with GAD at low and high doses relative to placebo and lorazepam following 3 and 6 months of treatment.

• Country None
• organs None
• Specialty None

A Phase 1b/2, Open-Label, Dose-Finding Study to Evaluate Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB0010718C) in Combination with Either Crizotinib or PF-06463922 in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer ESTUDIO ABIERTO DE FASE IB/II, DE BÚSQUEDA DE DOSIS, PARA EVALUAR LA SEGURIDAD, LA EFICACIA, LA FARMACOCINÉTICA Y LA FARMACODINÁMICA DE AVELUMAB (MSB0010718C) EN COMBINACIÓN CON CRIZOTINIB O CON PF-06463922 EN PACIENTES CON CARCINOMA DE PULMÓN NO MICROCÍTICO METASTÁSICO O AVANZADO Phase 1b Primary Objective: - Group A (ALK-negative): To determine MTD and the recommended Phase 2 dose (RP2D) of the combination of avelumab with crizotinib. - Group B (ALK-positive): To determine th...

• Country None
• organs None
• Specialty None

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB (PF-04383119) IN SUBJECTS WITH CANCER PAIN PREDOMINANTLY DUE TO BONE METASTASIS RECEIVING BACKGROUND OPIOID THERAPY -Demonstrate superior analgesic efficacy of tanezumab 20 mg SC versus matching placebo SC at Week 8 in subjects, with cancer pain predominantly due to bone metastasis, receiving background opioid ther...

• Country None
• organs None
• Specialty None

A study to evaluate the safety and efficacy of PF-06650833 in subjects with moderate to severely active rheumatoid arthritis who have an incomplete response to methotrexate treatment Estudio para evaluar la eficacia y seguridad de PF-06650833 en sujetos con artritis reumatoide de moderada a severa que han presentado una respuesta inadecuada a metotrexato (MTX) To evaluate the efficacy of PF-06650833 at 12 weeks, in subjects with moderate - severe active RA who have had an inadequate response to methotrexate. Evaluar la eficacia de PF-06650833 a las 1...

• Country None
• organs None
• Specialty None

A PHASE 2 MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MULTIPLE DOSES OF PF-04360365 IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE Primary Objectives: 1. To examine the safety and tolerability of PF-04360365 in subjects with mild-to moderate AD dosed for 18 months and followed for a total of 24 months; 2. To characterize the ...

• Country None
• organs None
• Specialty None

A 52-WEEK OPEN-LABEL SAFETY STUDY OF PD 0332334 IN SUBJECTS WITH GENERALIZED ANXIETY DISORDER Primary Objectives: • To assess the long-term safety and tolerability of 350 to 600 mg/day of PD-0332334 dosed BID in subjects with GAD.

• Country None
• organs None
• Specialty None